{
    "ticker": "EWTX",
    "name": "Erasca, Inc.",
    "description": "Erasca, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for patients with cancer. Founded in 2018 and headquartered in San Diego, California, Erasca aims to transform the treatment landscape for patients suffering from genetically defined cancers by leveraging advanced technologies and precision medicine. The company's core mission is to create targeted therapies that address the underlying genetic drivers of disease, thereby improving outcomes and reducing side effects compared to traditional treatments. Erasca is actively developing a pipeline of product candidates that include small molecules and monoclonal antibodies, specifically designed to inhibit key oncogenic pathways. The company's lead product candidate is designed to target RAS-driven tumors, which represent a significant area of unmet medical need in oncology. With a strong commitment to scientific innovation, Erasca collaborates with leading academic institutions and research organizations to advance its drug discovery and development efforts. As it progresses through clinical trials, Erasca remains dedicated to bringing hope and new treatment options to cancer patients and their families.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2018",
    "website": "https://www.erasca.com",
    "ceo": "Jack Taunton",
    "social_media": {
        "twitter": "https://twitter.com/ErascaInc",
        "linkedin": "https://www.linkedin.com/company/erasca/"
    },
    "investor_relations": "https://investors.erasca.com",
    "key_executives": [
        {
            "name": "Jack Taunton",
            "position": "CEO"
        },
        {
            "name": "Michael A. Weiser",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapies",
            "products": [
                "Lead Product Candidate for RAS-driven tumors",
                "Additional Pipeline Candidates"
            ]
        }
    ],
    "seo": {
        "meta_title": "Erasca, Inc. | Innovative Cancer Therapies",
        "meta_description": "Erasca, Inc. is dedicated to developing innovative therapies for cancer patients. Explore our mission, pipeline, and commitment to precision medicine.",
        "keywords": [
            "Erasca",
            "Biotechnology",
            "Cancer Treatment",
            "Precision Medicine",
            "Oncology",
            "RAS-driven tumors"
        ]
    },
    "faq": [
        {
            "question": "What is Erasca focused on?",
            "answer": "Erasca focuses on developing innovative therapies for patients with genetically defined cancers."
        },
        {
            "question": "Who is the CEO of Erasca?",
            "answer": "Jack Taunton is the CEO of Erasca, Inc."
        },
        {
            "question": "Where is Erasca headquartered?",
            "answer": "Erasca is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is Erasca's lead product candidate?",
            "answer": "Erasca's lead product candidate targets RAS-driven tumors."
        },
        {
            "question": "When was Erasca founded?",
            "answer": "Erasca was founded in 2018."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "EXEL",
        "CLVS"
    ],
    "related_stocks": [
        "BMY",
        "JNJ",
        "PFE",
        "GILD"
    ]
}